K-Group Beta Report issue

For profit Phase 1 Phase 2
Founded: San Diego California United States (2019)

Organization Overview

First Clinical Trial
2019
NCT04158336
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

K-Group Alpha | K-Group Alpha, Inc. | K-Group Beta

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Melanoma (Phase 2)

Ovarian Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 9